This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutPathogen CoveragePatient Risk FactorsAntimicrobial Subscription Model PilotDosingDosingDosingPreparation GuideShelf Life and StorageEfficacy & SafetyEfficacy & SafetyMechanism of ActionREPROVE Phase III trial(HAP/VAP)RECLAIM Phase III trial(cIAI)RECAPTURE Phase III trial(cUTI)REPRISE Phase III trial(cIAI and cUTI)Safety and TolerabilityEfficacy and Safety Data for Paediatric PatientsSupport & ResourcesSupport & ResourcesAMS ResourcesSepsisWebinars (Live and On-demand)KOL Videos - ZaviceftaKOL Videos - Gram-negativeKOL Videos - Clinical experienceVideosMaterials

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

For patients requiring treatment of infections due to resistant, aerobic Gram-negative bacteriaZAVICEFTA®: A combination of ceftazidime and avibactam1

Avibactam is a β-lactamase inhibitor combined with ceftazidime, a cephalosporin with established clinical experience2

ZAVICEFTA: Potent inhibitory activity against difficult-to-treat infections due to aerobic Gram-negative bacteria1,2

Avibactam inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including1*:
•    ESBLs
•    KPCs
•    OXA-48 carbapenemases
•    AmpC enzymes

*Avibactam does not inhibit class B enzyme​​​​​​​s (metallo-β-lactamases) and is not able to inhibit many class D enzymes1.

ZAVICEFTA is effective against infections with Enterobacteriaceae and P. aeruginosa with EUCAST minimum inhibitory concentrations as follows1:

Scroll left to view table
Organisms Susceptible Resistant
Enterobacteriaceae ≤ 8 mg/L > 8 mg/L
P. aeruginosa ≤ 8 mg/L > 8 mg/L
Pathogen coverage

ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.

Read more Loading
Patient Risk factors

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.

Read more Loading

Abbreviations:​​​​​​​

​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; CrCl, creatinine clearance; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing;

Prescribing information

Click here for Zavicefta (ceftazidime and avibactam) Prescribing Information

References

ZAVICEFTA. Summary of Product CharacteristicsLiscio JL, et al. Int J Antimicrob Agents 2015;46:266–71Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9Mazuski JE, et al. Surg Infect 2017;18:1–76Bonine NG, et al. Am J Med Sci 2019;357:102–10
PP-ZVA-GBR-1723. February 2023
Learn more about ZAVICEFTA’s Phase III clinical trials in adult patients with cUTI, cIAI and HAP/VAP. Learn more about efficacy Loading Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials. View tolerability profile LoadingZAVICEFTA’ s indications and its role in clinical practice

Dr Matthew Dryden, Consultant Microbiologist at Hampshire Hospitals presents ZAVICEFTA’ s indications and its role in clinical practice. ​​

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​